Pub Date : 2026-03-02DOI: 10.1158/2159-8290.CD-25-2137
Alexander A Azizi, Tej Pandya, Charles Swanton
Lung adenocarcinoma arising in individuals who have never smoked is understudied, represents a substantial global health burden, and is genomically distinct from smoking-associated disease. Zhao and colleagues have identified transcriptomic subtypes with prognostic value, including in stage I disease, supporting phenotypic state as an important determinant of outcome for lung adenocarcinoma in individuals who have never smoked. See related article by Zhao et al., p. 460.
{"title":"Transcriptomic Subtypes Are Associated with Clinical Outcomes for Patients with Lung Adenocarcinoma Who Have Never Smoked.","authors":"Alexander A Azizi, Tej Pandya, Charles Swanton","doi":"10.1158/2159-8290.CD-25-2137","DOIUrl":"10.1158/2159-8290.CD-25-2137","url":null,"abstract":"<p><p>Lung adenocarcinoma arising in individuals who have never smoked is understudied, represents a substantial global health burden, and is genomically distinct from smoking-associated disease. Zhao and colleagues have identified transcriptomic subtypes with prognostic value, including in stage I disease, supporting phenotypic state as an important determinant of outcome for lung adenocarcinoma in individuals who have never smoked. See related article by Zhao et al., p. 460.</p>","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"16 3","pages":"423-425"},"PeriodicalIF":33.3,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147324623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-02DOI: 10.1158/2159-8290.CD-RW2026-018
{"title":"High-Plasticity Cell State Drives Lung Cancer Progression and Drug Resistance.","authors":"","doi":"10.1158/2159-8290.CD-RW2026-018","DOIUrl":"10.1158/2159-8290.CD-RW2026-018","url":null,"abstract":"","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":" ","pages":"OF1"},"PeriodicalIF":33.3,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146117974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-02DOI: 10.1158/2159-8290.CD-25-1792
Heather R Christofk, Gina M DeNicola, Brooke M Emerling, Jeffrey A Engelman, David A Fruman, Marcus D Goncalves, Katja A Lamia, Costas A Lyssiotis, Brendan D Manning, Reuben J Shaw, Alex Toker, Matthew G Vander Heiden, Michael B Yaffe
{"title":"A Legacy of Mentorship: A Tribute to Lewis Cantley.","authors":"Heather R Christofk, Gina M DeNicola, Brooke M Emerling, Jeffrey A Engelman, David A Fruman, Marcus D Goncalves, Katja A Lamia, Costas A Lyssiotis, Brendan D Manning, Reuben J Shaw, Alex Toker, Matthew G Vander Heiden, Michael B Yaffe","doi":"10.1158/2159-8290.CD-25-1792","DOIUrl":"https://doi.org/10.1158/2159-8290.CD-25-1792","url":null,"abstract":"","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"16 3","pages":"431-438"},"PeriodicalIF":33.3,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147324497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-02DOI: 10.1158/2159-8290.CD-RW2026-010
{"title":"Newly Described Cell Death Pathway May Provide Therapeutic Opportunity.","authors":"","doi":"10.1158/2159-8290.CD-RW2026-010","DOIUrl":"10.1158/2159-8290.CD-RW2026-010","url":null,"abstract":"","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":" ","pages":"OF1"},"PeriodicalIF":33.3,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146060227","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-02DOI: 10.1158/2159-8290.CD-25-1758
Lewis C Cantley
{"title":"A Legacy of Enduring Discovery.","authors":"Lewis C Cantley","doi":"10.1158/2159-8290.CD-25-1758","DOIUrl":"https://doi.org/10.1158/2159-8290.CD-25-1758","url":null,"abstract":"","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"16 3","pages":"419-420"},"PeriodicalIF":33.3,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147324542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-02DOI: 10.1158/2159-8290.CD-25-2277
Yubin Zhou, Yun Huang
In this issue, Köhnke, Karigane, and colleagues applied allele-specific CRISPR/Cas9 correction in human acute myeloid leukemia samples to dissect the stage-specific functions of DNA methyltransferase 3A (DNMT3A) arginine 882 (R882) mutations. They demonstrate that DNMT3A R882 mutations are required to sustain self-renewal and inflammatory programs in preleukemic cells but become largely dispensable once leukemia is established, while still influencing leukemia stem cell frequency, thereby providing a strong preclinical rationale to reconsider the therapeutic window for targeting DNMT3A-mutant clones early in leukemogenesis. See related article by Köhnke et al., p. 592.
{"title":"Early Driver, Late Bystander: Stage-Specific Roles of DNMT3A R882 Mutations Unveiled in Human AML.","authors":"Yubin Zhou, Yun Huang","doi":"10.1158/2159-8290.CD-25-2277","DOIUrl":"10.1158/2159-8290.CD-25-2277","url":null,"abstract":"<p><p>In this issue, Köhnke, Karigane, and colleagues applied allele-specific CRISPR/Cas9 correction in human acute myeloid leukemia samples to dissect the stage-specific functions of DNA methyltransferase 3A (DNMT3A) arginine 882 (R882) mutations. They demonstrate that DNMT3A R882 mutations are required to sustain self-renewal and inflammatory programs in preleukemic cells but become largely dispensable once leukemia is established, while still influencing leukemia stem cell frequency, thereby providing a strong preclinical rationale to reconsider the therapeutic window for targeting DNMT3A-mutant clones early in leukemogenesis. See related article by Köhnke et al., p. 592.</p>","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"16 3","pages":"428-430"},"PeriodicalIF":33.3,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147324647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-02DOI: 10.1158/2159-8290.CD-RW2026-017
{"title":"Synthetic Storage of Transcripts Captures Hidden States Driving Drug Resistance.","authors":"","doi":"10.1158/2159-8290.CD-RW2026-017","DOIUrl":"10.1158/2159-8290.CD-RW2026-017","url":null,"abstract":"","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":" ","pages":"OF1"},"PeriodicalIF":33.3,"publicationDate":"2026-03-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146112467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-27DOI: 10.1158/2159-8290.cd-nw2026-0019
In a small adjuvant trial of patients with early-stage triple-negative breast cancer, a personalized mRNA neoantigen vaccine induced robust, multitarget T-cell responses that persisted for years. Notably, the vaccine was administered on its own, without concurrent chemotherapy or checkpoint blockade, highlighting the treatment’s stand-alone potential to drive durable antitumor immunity.
{"title":"Personalized mRNA Vaccine Spurs Lasting Immunity in TNBC","authors":"","doi":"10.1158/2159-8290.cd-nw2026-0019","DOIUrl":"https://doi.org/10.1158/2159-8290.cd-nw2026-0019","url":null,"abstract":"In a small adjuvant trial of patients with early-stage triple-negative breast cancer, a personalized mRNA neoantigen vaccine induced robust, multitarget T-cell responses that persisted for years. Notably, the vaccine was administered on its own, without concurrent chemotherapy or checkpoint blockade, highlighting the treatment’s stand-alone potential to drive durable antitumor immunity.","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"1 1","pages":""},"PeriodicalIF":28.2,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147314848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-27DOI: 10.1158/2159-8290.cd-nw2026-0020
Findings from a phase I study show that the p53 reactivator rezatapopt is safe and can elicit responses in patients with a range of solid tumors containing the Y220C mutation. Although the drug was ineffective in tumors with KRAS mutations, and whether the strategy can be applied to more common missense mutations remains unclear, the findings offer proof of concept for p53 reactivation.
{"title":"“Pioneering” p53 Reactivator Shows Proof-of-Concept in Phase I Trial","authors":"","doi":"10.1158/2159-8290.cd-nw2026-0020","DOIUrl":"https://doi.org/10.1158/2159-8290.cd-nw2026-0020","url":null,"abstract":"Findings from a phase I study show that the p53 reactivator rezatapopt is safe and can elicit responses in patients with a range of solid tumors containing the Y220C mutation. Although the drug was ineffective in tumors with KRAS mutations, and whether the strategy can be applied to more common missense mutations remains unclear, the findings offer proof of concept for p53 reactivation.","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"67 1","pages":""},"PeriodicalIF":28.2,"publicationDate":"2026-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147314847","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}